We are thrilled to announce a significant collaboration that holds immense promise for the cancer care landscape.

Carevive Systems, a pioneering oncology-focused health technology company, is now partnering with Clinical Outcomes Solutions (COS), a global leader in the collection, analysis, and reporting of patient-centered outcomes data. This partnership marks a pivotal step towards advancing personalized drug development and elevating the patient experience in cancer care.

In alignment with our shared vision and expertise in the realm of oncology data, COS and Carevive are excited to welcome Carevive to the Oncology Outcomes initiative – an initiative first launched by COS in February 2019. This initiative aims to harness the power of data analysis to revolutionize patient experience and survival outcomes in the realm of cancer care.

Carevive’s innovative digital oncology platform, PROmpt®, will play a pivotal role in capturing the patient experience during treatment. Combined with COS’ extensive experience in analyzing such data, this collaboration is set to offer invaluable insights to life science companies and regulatory bodies.

One of the highlights of this partnership is Carevive’s platform, which empowers cancer care teams to remotely monitor and manage patients, leading to enhanced patient quality of life and survival outcomes. The platform’s capabilities extend to large-scale digital data collection via the Oncology Pragmatic Trial Investigator Network (Carevive OPT-IN®), merging electronic medical records (EMR) with patient-reported outcomes (PRO). This integrated approach provides a comprehensive view of cancer patient populations, fostering quality improvements and pathway enhancements.

COS, recognized for its prowess in capturing and communicating the patient voice, is dedicated to delivering actionable evidence through qualitative and quantitative research, with a specialized focus on Clinical Outcomes Assessments in the oncology arena. With this partnership, COS will further amplify its expertise by providing data analytic support to glean insights from novel patient experience datasets.

Stacie Hudgens, CEO of COS, shared her excitement about this partnership:

“We are very excited to announce this partnership with Carevive, an organization that shares our deep-rooted passion for world-class oncology research to improve the patient experience.”

Stacie Hudgens
CEO of COS

Bruno Lempernesse, CEO of Carevive, echoes this sentiment, stating:

“By combining COS’ FDA and industry expertise with Carevive data, this partnership provides a model of how to approach real-world evidence and patient-reported outcomes with cancer care teams, regulatory authorities, and life science companies.”

Bruno Lempernesse
CEO of Carevive

Tara Symonds, COS Chief Science Officer, emphasized the transformative impact of real-time patient symptom monitoring during treatment across various cancer types. She underlined that this approach enables quicker interventions and improved patient experiences, ultimately contributing to extended survival. Such insights are vital for evaluating the effectiveness of treatments and enhancing symptom management.

“We have seen the benefit from monitoring patient symptoms over time while on treatment across numerous cancer types. Oncology treatments are highly toxic and can cause significant side effects. Thus, effective, real-time monitoring enables far quicker intervention and the opportunity to improve the patient experience and enhance symptom management.

Tara Symonds
COS Chief Science Officer

This collaboration ushers in a new era of cancer care, empowered by data-driven insights and patient-centric approaches. The COS and Carevive partnership stands as a beacon of hope for patients, caregivers, and the entire healthcare community.